<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647189</url>
  </required_header>
  <id_info>
    <org_study_id>DIVA-001</org_study_id>
    <nct_id>NCT03647189</nct_id>
  </id_info>
  <brief_title>Randomized, Controlled Trial With Hybrid Fractional Laser</brief_title>
  <official_title>Randomized, Controlled Trial With Hybrid Fractional Laser for Vulvovaginal Atrophy in Breast Cancer Survivors and Menopausal Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sciton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled trial will evaluate hybrid fractional laser treatment for&#xD;
      vulvovaginal atrophy in breast cancer survivors and menopausal females&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Vaginal health index score (VHIS)</measure>
    <time_frame>6 months</time_frame>
    <description>Scores vaginal health by scoring it from 1(none) - 5(excellent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Female sexual function index questionnaire (FSFI)</measure>
    <time_frame>6 months</time_frame>
    <description>Scoring 0(minimum) - 5(maximum)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in day-to-day impact of vaginal aging questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in histology</measure>
    <time_frame>3 months</time_frame>
    <description>Histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in photography</measure>
    <time_frame>6 months</time_frame>
    <description>Photography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with hybrid fractional laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Fractional Laser</intervention_name>
    <description>Hybrid Fractional Laser</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Healthy biological female aged between 40 to 70 years 2. Is post-menopausal with a&#xD;
             AND b OR c:&#xD;
&#xD;
               1. No menses for at least 12 months&#xD;
&#xD;
               2. Follicle-stimulating hormone (FSH) level over 40mlU/mL&#xD;
&#xD;
               3. Has had a bilateral oophorectomy at least 12 months ago with no hormone&#xD;
                  replacement 3. Is experiencing at least two self-reported symptoms of GSM, such&#xD;
                  as&#xD;
&#xD;
               1. Vaginal irritation in the absence of infection&#xD;
&#xD;
               2. Chronic burning sensation&#xD;
&#xD;
               3. Chronic itching in the absence of infection&#xD;
&#xD;
               4. Recurring urinary tract infections (UTIs)&#xD;
&#xD;
               5. Vaginal dryness during sexual activity&#xD;
&#xD;
               6. Pain during sexual activity (dyspareunia) 4. Has been experiencing symptoms of&#xD;
                  GSM for greater than 3 months 5. Is unable due to a medical contraindication or&#xD;
                  unwilling to receive hormone-based vaginal therapy 6. Early menopause after&#xD;
                  breast cancer 7. Normal and up to date pap smear, if applicable 8. Is sexually&#xD;
                  active (i.e. intravaginal intercourse) or has the potential and desire to be&#xD;
                  sexually active if symptoms of GSM improve 9. Can read, understand and sign&#xD;
                  informed consent form 10. Has indicated willingness to participate in the study&#xD;
                  by signing an informed consent form 11. Agrees to adhere to the treatment and&#xD;
                  follow-up schedule and post treatment care instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Undiagnosed abnormal genital bleeding 2. Has history of pelvic surgery or other&#xD;
             energy-based vaginal therapy within 12 months prior to enrollment 3. Previous use of&#xD;
             topical estrogen therapy within the last 6 months 4. Has used vaginal creams,&#xD;
             moisturizers, lubricants or homeopathic preparations, or received anticoagulants,&#xD;
             antiplatelet, thrombolytic, vitamin E or anti-inflammatory within 2 weeks of treatment&#xD;
             5. Has history of heart failure 6. Has equal to or greater than stage III prolapse,&#xD;
             according to pelvic organ prolapse quantification system (POP-Q) 7. Has an active&#xD;
             sexually transmitted infection (STI) 8. Has signs or symptoms of vulvitis/vaginitis 9.&#xD;
             Has signs or symptoms of acute urinary tract infection (UTI) 10. Has participated in&#xD;
             any clinical trial involving an investigational drug or procedure within past 30 days&#xD;
             11. The investigator feels that for any reason the subject is not eligible to&#xD;
             participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Miamim Dermatology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspareunia</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

